Blueprint Medicines Corporation Common Stock SALES AGREEMENT Sales Agreement • July 31st, 2020 • Blueprint Medicines Corp • Pharmaceutical preparations • New York
Blueprint Medicines Corporation, a Delaware Corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. COLLABORATION AGREEMENT by and among Blueprint Medicines Corporation, F....Collaboration Agreement • July 31st, 2020 • Blueprint Medicines Corp • Pharmaceutical preparations
THIS COLLABORATION AGREEMENT (this “Agreement”) is entered into as of July 13, 2020 (the “Effective Date”) by and among BLUEPRINT MEDICINES CORPORATION, having its principal place of business at 45 Sidney Street, Cambridge, MA 02139, United States (“BPM”), F. Hoffmann-La Roche Ltd, having a principal office at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche Basel”), and Genentech, Inc., have a principal office at 1 DNA Way, South San Francisco, California 94080, U.S.A. (“Genentech”; Roche Basel and Genentech together referred to as “Roche”). BPM and Roche are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used but not defined in the Background below shall have the meanings ascribed to such terms in Article 1 or elsewhere in this Agreement.
